Class information for:
Level 1: DAPTOMYCIN//TELAVANCIN//HVISA

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
2629 2115 35.4 80%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
116 23742 STAPHYLOCOCCUS AUREUS//MRSA//METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 DAPTOMYCIN Author keyword 355 66% 16% 328
2 TELAVANCIN Author keyword 140 88% 3% 66
3 HVISA Author keyword 94 94% 2% 33
4 DALBAVANCIN Author keyword 64 75% 2% 47
5 LIPOGLYCOPEPTIDE Author keyword 62 85% 2% 33
6 ORITAVANCIN Author keyword 42 69% 2% 36
7 VANCOMYCIN Author keyword 26 11% 11% 231
8 ANTIINFECT Address 22 27% 3% 71
9 VISA Author keyword 22 38% 2% 45
10 VANCOMYCIN TOLERANCE Author keyword 18 89% 0% 8

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 DAPTOMYCIN 355 66% 16% 328 Search DAPTOMYCIN Search DAPTOMYCIN
2 TELAVANCIN 140 88% 3% 66 Search TELAVANCIN Search TELAVANCIN
3 HVISA 94 94% 2% 33 Search HVISA Search HVISA
4 DALBAVANCIN 64 75% 2% 47 Search DALBAVANCIN Search DALBAVANCIN
5 LIPOGLYCOPEPTIDE 62 85% 2% 33 Search LIPOGLYCOPEPTIDE Search LIPOGLYCOPEPTIDE
6 ORITAVANCIN 42 69% 2% 36 Search ORITAVANCIN Search ORITAVANCIN
7 VANCOMYCIN 26 11% 11% 231 Search VANCOMYCIN Search VANCOMYCIN
8 VISA 22 38% 2% 45 Search VISA Search VISA
9 VANCOMYCIN TOLERANCE 18 89% 0% 8 Search VANCOMYCIN+TOLERANCE Search VANCOMYCIN+TOLERANCE
10 GRAM POSITIVE INFECTIONS 17 49% 1% 25 Search GRAM+POSITIVE+INFECTIONS Search GRAM+POSITIVE+INFECTIONS

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 SIMULATED ENDOCARDIAL VEGETATIONS 112 89% 2% 50
2 REDUCED SUSCEPTIBILITY 102 33% 12% 252
3 LY146032 87 79% 3% 56
4 VANCOMYCIN INTERMEDIATE 87 65% 4% 83
5 TD 6424 79 91% 2% 32
6 BI 397 73 96% 1% 23
7 MINIMUM INHIBITORY CONCENTRATION 73 45% 6% 120
8 COMPLICATED SKIN 72 37% 7% 157
9 MU50 70 86% 2% 36
10 ONCE WEEKLY DALBAVANCIN 69 81% 2% 42

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
The Clinical Significance of Vancomycin Minimum Inhibitory Concentration in Staphylococcus aureus Infections: A Systematic Review and Meta-analysis 2012 163 56 77%
Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications 2010 239 342 61%
Potential Role for Telavancin in Bacteremic Infections Due to Gram-Positive Pathogens: Focus on Staphylococcus aureus 2015 4 44 84%
The clinical positioning of telavancin in Europe 2015 2 48 79%
New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance 2012 82 82 46%
New Lipoglycopeptides A Comparative Review of Dalbavancin, Oritavancin and Telavancin 2010 55 70 87%
Systematic Review and Meta-Analysis of Linezolid versus Daptomycin for Treatment of Vancomycin-Resistant Enterococcal Bacteremia 2014 16 22 59%
A Current Perspective on Daptomycin for the Clinical Microbiologist 2013 18 190 81%
Mechanisms of vancomycin resistance in Staphylococcus aureus 2014 9 55 82%
Daptomycin: The role of high-dose and combination therapy for Gram-positive infections 2013 18 75 77%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ANTIINFECT 22 27% 3.4% 71
2 EUGENE PLEBAUM PHARM HLTH SCI 9 13% 3.1% 66
3 MOL GENET ANTIMICROBIAL ISTANCE UNIT 8 39% 0.8% 16
4 PHARM PRACTICE 4148 7 67% 0.3% 6
5 AUSTIN INFECT 5 47% 0.4% 8
6 PAEDIAT PATHOL MOL BIOMED SCI 4 75% 0.1% 3
7 ANTI INFECT 4 25% 0.7% 14
8 ANTIBIOT ISTANCE MOBILE ELEMENTS GRP 4 44% 0.3% 7
9 MADISON PHARM 3 43% 0.3% 6
10 MICROBIOL DIAGNOST UNITPUBL HLTH 3 60% 0.1% 3

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000211283 CEFTAROLINE//CEFTOBIPROLE//CEFTOLOZANE TAZOBACTAM
2 0.0000201614 SECTOR MICROBIOL//STAPHYLOCOCCUS AUREUS BACTEREMIA//STAPHYLOCOCCUS AUREUS BACTERAEMIA
3 0.0000197781 LINEZOLID//OXAZOLIDINONE//LINEZOLID RESISTANCE
4 0.0000173593 VANCOMYCIN//TEICOPLANIN//FUNCEI
5 0.0000142262 TIGECYCLINE//GLYCYLCYCLINE//GLYCYLCYCLINES
6 0.0000118448 DALFOPRISTIN//QUINUPRISTIN//QUINUPRISTIN DALFOPRISTIN
7 0.0000098228 MECA GENE//MECA//METHICILLIN RESISTANCE
8 0.0000097786 PANTON VALENTINE LEUKOCIDIN//MRSA//CA MRSA
9 0.0000065530 ENTEROCOCCUS//VANA//ENTEROCOCCI
10 0.0000059941 MOYNE PREVENT MED//AGR//HUMAN BACTERIAL PATHOGENESIS